Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

30-05-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: Final analysis of KEYNOTE-189

Delvys Rodriguez-Abreu reports the final analysis of the KEYNOTE-189 trial of pembrolizumab plus chemotherapy for patients with nonsquamous non-small-cell lung cancer (4:51).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Related content

17-03-2020 | Non-small-cell lung cancer | News

KEYNOTE-189 shows continued NSCLC benefit of pembrolizumab–chemotherapy

09-09-2019 | Non-small-cell lung cancer | Conference coverage | News

TMB does not predict NSCLC pembrolizumab–chemotherapy response

27-02-2020 | Non-small-cell lung cancer | News

QoL data further support first-line pembrolizumab–chemotherapy for advanced NSCLC

09-10-2019 | Non-small-cell lung cancer | Editorial | Article

Current therapies for advanced NSCLC: The role of maintenance therapy in an immunotherapy world
Image Credits